Compare MFIC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | ACHV |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.6M | 726.5M |
| IPO Year | 2004 | 2018 |
| Metric | MFIC | ACHV |
|---|---|---|
| Price | $9.05 | $8.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $11.25 | ★ $14.67 |
| AVG Volume (30 Days) | 453.9K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.97 | $2.62 |
| 52 Week High | $12.50 | $8.64 |
| Indicator | MFIC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 56.47 |
| Support Level | N/A | $4.11 |
| Resistance Level | $9.95 | $8.63 |
| Average True Range (ATR) | 0.17 | 0.38 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 6.67 | 56.75 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.